Meeting
2018 Gastrointestinal Cancers Symposium
Oxaliplatin (OX), chronomodulated capecitabine, and UGT1A1 genotype-directed dosing of irinotecan (IR) triplet chemotherapy (OXIRI) in patients (pts) with advanced pancreatic cancer (APC).
Authors
Amanda Oon Lim Seet
National Cancer Center, Singapore, Singapore
Amanda Oon Lim Seet , Sylvia Chen , Yingnan Yu , Su Pin Choo , David Wai-Meng Tai , Justina Yick Ching Lam , Yvonne Chang , Balram Chowbay , Matthew CH Ng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02368860
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 411)
DOI
10.1200/JCO.2018.36.4_suppl.411
Abstract #
411
Poster Bd #
K4
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Prognostic and predictive value of circulating tumour DNA (ctDNA) by amplicon-based next generation sequencing (NGS) of advanced pancreatic cancer (APC) in a phase I trial of oxaliplatin capecitabine and irinotecan (OXIRI) triplet chemotherapy.
First Author: Amanda Oon Lim Seet
Poster
2018 Gastrointestinal Cancers Symposium
FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 polymorphism: A multicenter, retrospective study.
First Author: Kumiko Umemoto
Poster
2016 Gastrointestinal Cancers Symposium
Second-line chemotherapy by FOLFIRINOX with unresectable pancreatic cancer (phase I, II study).
First Author: Noritoshi Kobayashi
Poster
2020 ASCO Virtual Scientific Program
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study.
First Author: Hortense Chevalier